(Q37902509)

25 August 2017

1 reference

title

Treatment of pulmonary arterial hypertension with targeted therapies (English)

1 reference

25 August 2017

arterial hypertension

0 references

author

David Montani

series ordinal

3

1 reference

25 August 2017

4

Xavier Jaïs

1 reference

25 August 2017

7

Marc Humbert

1 reference

25 August 2017

6

Gérald Simonneau

1 reference

PubMed ID

21769113

25 August 2017

Dermot S. O'Callaghan

series ordinal

1

object named as

Dermot S O'Callaghan

1 reference

25 August 2017

5

Olivier Sitbon

1 reference

25 August 2017

Laurent Savale

2

1 reference

PubMed ID

21769113

25 August 2017

language of work or name

English

0 references

publication date

19 July 2011

1 reference

Nature Reviews Cardiology

25 August 2017

1 reference

25 August 2017

8

1 reference

25 August 2017

9

1 reference

25 August 2017

526-538

1 reference

Pulmonary arterial hypertension in France: results from a national registry

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

An epidemiological study of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Diagnosis and assessment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Improving survival in idiopathic pulmonary arterial hypertension: revisiting the "kingdom of the near-dead".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Bloodstream infections in patients given treatment with intravenous prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term outcome with intravenous iloprost in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Effects of long-term bosentan in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Bosentan therapy for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Combination therapy and new types of agents for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its act

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long term imatinib treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pulmonary hypertension: therapeutic targets within the serotonin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Increased plasma serotonin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Simvastatin as a treatment for pulmonary hypertension trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Hypoxia during air travel in adults with pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

The role of thrombosis in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Experience with inhaled iloprost and bosentan in portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Bosentan therapy for pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Inhalation of vasoactive intestinal peptide in pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

Primary pulmonary hypertension: natural history and the importance of thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.104

VIP-mediated G protein-coupled Ca2+ influx activates a constitutive NOS in dispersed gastric muscle cells

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21769113

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21769113

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2011.104

1 reference

25 August 2017

1 reference

PubMed ID

21769113